Articles tagged with Brain Tumors
Researchers have discovered potential regulatory networks in glioblastoma using microRNAs and transcription factors. The study identified 54 feed-forward loops with functions important to carcinogenesis and unique functions specific to each FFL.
A Phase I clinical trial found that the experimental vaccine ICT-107 targets six antigens found on glioblastoma cells and three on cancer stem cells, improving immune responses and progression-free survival rates in patients. The study also showed that targeting these antigens may be a viable strategy for treating glioblastoma.
A new glioblastoma vaccine has demonstrated safety and effectiveness in a Phase 2 clinical trial, extending median survival to 11 months for patients with recurrent brain cancer. The vaccine was found to induce an immune response against tumor-specific targets, suggesting potential for improved treatment outcomes.
Scientists at Penn State College of Medicine have created a new approach to treating brain tumors by targeting the ferritin protein with siRNA. By reducing ferritin levels in cancer cells, the sensitivity to chemotherapy can be increased, allowing for lower doses and potentially fewer side effects.
A study found that a specific gene change can predict which brain cancer patients respond well to treatment, allowing for personalized therapy. The gene MGMT methylation status was associated with improved overall and progression-free survival in patients treated with radiation and chemotherapy.
Researchers found that cancer cells induce oxidative stress in normal connective tissue to extract vital nutrients, accelerating aging and inflammation. This process can identify breast cancer patients at risk of metastasis and offers a potential therapeutic target via antioxidant and anti-inflammatory drugs.
Thurston worked with Dr. Nader Sanai to create a detailed Gantt chart, compressing the project timeline from five to three years and reducing expenses. The gift agreement includes financial incentives, motivating Dr. Sanai to achieve specific goals on a quarterly basis.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a method to enhance the functionality of killer T-cells, which can help fight melanoma and other cancers. The study found that priming killer T cells with IL-12 increased their ability to recognize and target cancer cells.
Researchers at Albert Einstein College of Medicine have identified Aurora A as a critical target for therapies against rhabdoid tumors, a rare and aggressive childhood cancer. The study found that the loss of a tumor suppressor gene leads to increased expression of Aurora A, which is essential for tumor growth.
A new study suggests that damage to surrounding tissue during chemoradiation for high-grade glioma may play a role in determining long-term outcome and overall survival. Patients who experienced fewer side effects lived 4 months longer compared to those who did not.
Rafael Davalos has developed a method to treat cancerous tumors using irreversible electroporation, achieving complete remission in a seven-year-old dog. He aims to explore its potential in treating other pathologies, such as cardiac arrhythmias and glioblastoma multiforme.
A team of University of Cincinnati researchers is sequencing individual glioblastoma genomes and tracking abnormalities in the bloodstream to establish personalized biomarkers. The study aims to guide treatment efforts and identify new therapeutic targets for this aggressive brain tumor.
Researchers discovered that cancer cells generate a 'stress response' signal that induces nearby macrophages to issue a similar stress response, promoting inflammation and tumor development. This finding presents a potential target for tumor-specific therapies.
The annual report to the nation on cancer trends finds a slight decline in brain tumor incidence rates, with a notable increase in non-malignant tumors among adults. Non-malignant tumors were found to be twice as common as malignant tumors in this age group.
New research from St. Jude Children's Research Hospital scientists shows that mutations in three pathways cooperate to launch glioblastoma, an aggressive brain tumor. Tumors develop in multiple regions of the brain, highlighting the complexity and cooperation of genetic changes driving cancer.
A multidisciplinary team found that patients with tumors in the right parietal cortex struggled to process categorical spatial information, leading to errors in mental rotation tasks. The left prefrontal cortex was also affected, causing difficulties in setting up specific programs within the brain for task organization.
A new study will investigate 'ependymoma', a rare brain tumour type with low survival rates. The research aims to develop drugs called 'histone deacetylase inhibitors' to re-activate natural defence mechanisms against brain cancer.
Researchers at Stanford University School of Medicine have cultured human cells from Diffuse Intrinsic Pontine Glioma, a deadly pediatric brain tumor. The breakthrough allows for the development of new treatments and potential therapies targeting the Hedgehog signaling pathway.
Researchers identify Hunk as a key protein required for HER2/neu-induced mammary tumorigenesis, potentially leading to new treatments for aggressive breast cancer. A new compound, ABT-737, sensitizes human cancer cells to apoptosis in hypoxic regions, offering a potential combination therapy for solid tumors.
UBE4B is a molecule that binds to p53 and MDM2, allowing them to degrade the tumor-suppressing protein p53 in cancer cells. This discovery could lead to novel anti-cancer therapies and improve prognosis for cancer patients.
Researchers have found that tumor microvesicles contain segments of tumor DNA, including retrotransposons, which can transfer between cells. This discovery may help understand tumor progression and monitor treatment response.
Researchers have successfully destroyed tumors of human brain cancer cells in animal tests using light-activated nanoparticles. The treatment showed promising results, with over half of the treated animals remaining cancer-free after three months.
A targeted delivery combination has been developed to selectively cross the blood-brain barrier and bind to brain tumors, enabling imaging and treatment. The approach uses a peptide that mimics iron, binding agent glides through the blood-brain barrier to target glioblastoma tumors.
Glioblastoma cells can transform into blood vessel cells when oxygen is scarce, making treatment efforts less effective. This transformation allows the tumor cells to continue receiving nutrients and oxygen, leading to a resurgence of cancer growth.
Ryan Salinas, a 2nd-year medical student at UCSF, received the Lucien Rubenstein Award for his outstanding research on histone demathylase JMJD3 as a potential treatment target for glioblastoma. The American Brain Tumor Association selected Salinas from a group of 10 Medical Student Summer Fellows.
A study by researchers at Ohio State University found that an enzyme-armed virus can spread more effectively through brain tumors and improve survival rates. The enzyme helps the virus clear a path through protein molecules, allowing it to destroy cancer cells more efficiently.
Scientists at IRB Barcelona discovered that some brain tumors in fruit flies use the genetic program of germline cells to grow. Silencing specific genes leads to healthy brains, highlighting their crucial role in tumor development. This finding offers new insights into cancer research and potential treatment approaches.
Researchers found that arsenic trioxide inhibits the growth of medulloblastoma and Ewing sarcoma cell lines by blocking the Hedgehog/GLI1 signaling pathway. The compound improved survival in a mouse model of medulloblastoma, suggesting its potential as a therapeutic option.
The study found that overexpression of the Sox3 gene causes frequent XX male sex reversal, while a new regulatory pathway involving the ventral premammillary nucleus is linked to leptin's effect on puberty onset. Additionally, arsenic trioxide may be beneficial for treating certain brain tumors.
Researchers identify genetic alterations in medulloblastoma tumors, including mutations in tumor suppressor genes MLL2 and MLL3. This could lead to the development of targeted therapies for children with this type of brain cancer.
A new research paper published in the Journal of the National Cancer Institute reveals a genetic mutation that leads to abnormal metabolic processes in gliomas, potentially leading to targeted therapies. The study shows that almost all tumors with IDH mutations have the same methylation pattern.
A new study reveals that aggressive tumor cells lack the strong molecular 'glue' responsible for binding normal cells together. This allows tumor cells to break away, detach from their neighbors, and spread to other regions of the body.
Researchers have identified distinct subtypes of medulloblastoma brain tumors originating from unique cells, leading to different treatment approaches. The study's findings support the development of targeted therapies and aid in searching for combinations of cells and mutations that may lead to other cancers.
According to a 21-year study, surgery for acoustic neuromas achieves gross total resection in the vast majority of patients, resulting in minimal morbidity and mortality. The procedure also preserves facial function in 90% of cases, with 44% of patients regaining useful hearing in the affected ear.
A new study from Massachusetts General Hospital finds that circulating tumor cells prepare a hospitable environment for tumor growth by bringing along noncancerous cells, facilitating metastasis. The presence of these supporting cells is crucial for the initial growth and survival of tumors at a new site.
Researchers identified a crucial protein, LXR-beta, involved in the negative side effects of glucocorticoid drugs. Targeting this protein may lead to safer drug designs. Additionally, TXNL2 is found to protect human breast cancer cells from oxidative stress, while mutations in SLC1A1 cause rare kidney disorder dicarboxylic aminoaciduria.
A Mayo Clinic study found that aggressive surgery to completely remove low-grade brain tumors (gliomas) in children offers the highest chance of overall survival. If complete removal is not possible, adding radiation therapy yields similar results.
Researchers have identified six subtypes of childhood brain cancer medulloblastoma with distinct molecular profiles, allowing for more precise and individualized treatment. The study's findings could lead to the development of biomarkers for improved patient outcomes and more effective treatment strategies.
Researchers discovered that GPR124 controls the growth of blood vessels into the developing brains of mice embryos. The protein is essential for normal blood vessel development in the nervous system but can lead to abnormal hypervasculature when overexpressed.
Researchers create a nanobioconjugate drug that specifically targets glioblastoma multiforme by blocking the production of laminin-411, promoting tumor cell death. Human clinical trials are anticipated to begin soon, offering new hope for brain cancer treatment.
In a phase II study, patients with locally advanced and metastatic NSCLC experienced significant increases in survival time when treated with TTF therapy in combination with chemotherapy. The therapy has also been shown to have clinical efficacy in human trials for other solid tumors, including recurrent glioblastoma.
A vaccine that targets a genetic mutation driving aggressive glioblastoma improved patient survival, with median overall survival of 26 months compared to 15 months for control group. Limited side effects were reported.
A new vaccine has been shown to extend survival for patients with glioblastoma, the most deadly form of brain cancer, by eliminating aggressive cancer cells carrying the EGFRvIII marker. The study found that adding the vaccine to standard therapy improved median survival time from 15 months to 26 months.
Researchers at Washington University School of Medicine discovered a new drug target that can improve the effectiveness of radiation therapy for hard-to-treat cancers. The enzyme cytosolic phospholipase A2 (cPLA2) promotes tumor angiogenesis, enabling tumors to overcome radiation effects.
A novel combination therapy of temozolomide and a Notch inhibitor has been shown to be highly effective in reducing tumor growth and recurrence in glioblastoma multiforme. This approach aims to target cancer stem cells, which are resistant to traditional therapies.
Researchers at Georgia Institute of Technology develop a system to excavate brain tumor cells by directing them away from their location in the brain to a gel-based 'sink' where they can be removed or killed. The goal is to improve survival rates and reduce toxic effects of treatment for pediatric medulloblastomas.
Researchers at UCLA have developed a microfluidic image cytometry platform that can measure cell-signaling pathways in brain tumor samples at the single-cell level. This technology marks an advance toward predictive and personalized medicine, enabling physicians to predict patient prognosis and guide treatment.
Researchers have demonstrated the use of iron oxide nanoparticles to deliver antibodies to implanted brain tumors, enhancing tumor visibility via MRI while killing cancer cells. The particles also show potential for targeted therapy against glioblastoma multiforme, a common and aggressive primary brain tumor.
A study at the American Association of Physicists in Medicine meeting found that intensity modulated arc therapy can effectively treat brain tumors while reducing damage to surrounding sensitive tissues, such as ears and parts of the brain. This technique uses continuous rotation of X-ray sources around a patient during treatment.
The current standard of care for brain cancer triggers biological responses that may feed the disease, according to Boston College researchers. This can lead to an escalation of conditions favorable to tumor cell survival and growth.
A new study found that an enriched environment can reduce cancer growth in mice by activating a nervous system pathway that decreases leptin levels, a hormone linked to appetite and cancer growth. The effect was observed in models of melanoma and colon cancer, with tumors reduced by up to 80% after three weeks of enrichment.
Researchers identify a protein released by neural stem cells that induces signaling in glioblastoma cells, causing them to differentiate. This discovery could lead to new therapy concepts targeting tumor stem cells and potentially destroying the aggressive brain tumors.
A new experimental drug targeting the Hedgehog pathway has shown early signs of efficacy in pediatric brain tumor patients, with some still on treatment a year after diagnosis. The study's findings have given the green light for larger Phase II studies to advance targeted therapies against medulloblastomas.
A modified measles virus has been shown to effectively kill medulloblastoma cells in laboratory studies and mouse models, suggesting its potential as a new treatment option for childhood brain tumors. The vaccine strain targets the CD46 receptor, which is highly expressed in multiple tumor types.
A Northwestern University study found that brain cancer patients with malignant gliomas tend to overestimate their quality of life compared to their caregivers. The research suggests that caregivers play a crucial role in providing a more accurate assessment of the patient's well-being.
A new study identifies a crucial gene in pediatric high-grade glioma, which may lead to the development of more effective drugs. The research found that the PDGFRA gene is unusually active in childhood cancer and is likely to be an important drug target.
A study led by St. Jude Children's Research Hospital identified a cancer gene unusually active in some childhood brain tumors, providing a new treatment target for high-grade gliomas (HGGs). The research found significant differences between genetic defects in children and adults with HGG.
Researchers at Thomas Jefferson University found that hypofractionated stereotactic radiotherapy significantly improves survival rates for patients with recurrent brain cancers, while minimizing side effects. The treatment provides longer survival without experiencing common chemotherapy and targeted therapy side effects.
Researchers found that PDE5 inhibitors increase blood-brain barrier permeability to Herceptin, boosting effectiveness against lung and breast cancer brain metastases. The combination of vardenafil plus Herceptin improved survival by 20% in mouse models.
Researchers have found that parvoviruses can completely regress malignant brain tumors in rats and human gliomas. The viruses target cancer cells without affecting healthy tissue, making them a potential new approach to treating glioblastoma.